Session III - Systemic Treatment for Advanced Stage Non-Small Cell Lung Cancer
By: Joel Neal, MD, PhD, David Gandara, MD, Collin Blakely, MD, PhD, Karen Kelly, MD, Jonathan W. Riess, MD, MS
Lung Cancer With EGFR Exon 19 and L858R Mutations: The Optimal Front Line Therapy
By: Jonathan Riess, MD, MS
